Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
soficitinib
- Development stage
- Phase 3
- Lead developer
- InnoCare Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Soficitinib is a potent and selective small molecule inhibitor of Tyrosine Kinase 2 (TYK2) developed by InnoCare Pharma. It is currently under investigation for the treatment of various T-cell related autoimmune disorders, with a particular focus on dermatological conditions such as atopic dermatitis, vitiligo, and prurigo nodularis. The drug functions by modulating the JAK-STAT signaling pathway, in which TYK2 plays a crucial role, thereby inhibiting inflammatory responses and reducing symptoms like itching.
- Other names
- ICP-332ICP332ICP 332ICP-330ICP330ICP 330
02
Targets
JAK2 (Janus kinase 2)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on soficitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on soficitinib.